Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer

Table 1 Patient characteristics (n = 41)

Variables before primary androgen deprivation therapy
Median initial PSA, ng/mL (range)	176.0 (4.2-6500.0)
Gleason scores, n (%)
6-7	4 (9.8 %)
8-10	37 (90.2 %)
Clinical T, n (%)
≤T3	32 (78.0 %)
T4	9 (22.0 %)
Clinical N, n (%)
N0	14 (34.1 %)
N1	27 (65.9 %)
Clinical M, n (%)
M0	12 (29.3 %)
M1a	5 (12.2 %)
M1b	21 (51.2 %)
M1c	3 (7.3 %)
EOD, n (%)
0	17 (41.5 %)
1	4 (9.8 %)
2	4 (9.8 %)
3	7 (17.1 %)
4	9 (22.0 %)
Variables at docetaxel therapy induction
Median PSA, ng/mL (range)	56.8 (0.2-4715.0)
Median PSA doubling time, months (range)	1.4 (−3.8-47.1)
Median LDH, IU/L (range)	225 (135–1129)
Median Hb, g/dL (range)	11.7 (8.1-13.7)
Median Alb, g/dL (range)	3.9 (2.4-4.7)
Median ALP, IU/L (range)	278 (135–3296)
Median age, years (range)	73 (48–81)
EOD, n (%)
0	1 (2.4)
1	10 (24.4)
2	13 (31.7)
3	11 (26.8)
4	6 (14.6)
Median BSI, % (range)	2.4 (0.0-12.2)
BSI ≤1 %, n (%)	18 (43.9 %)
BSI >1 %, n (%)	23 (56.1 %)
Liver metastasis, n (%)
Yes	6 (14.96 %)
No	35 (85.4 %)
Local therapy (prostatectomy or radiation), n (%)
Yes	5 (12.2 %)
No	36 (87.8 %)

PSA prostate-specific antigen, LDH lactate dehydrogenase, Hb hemoglobin, Alb albumin, BSI bone scan index

ISSN: 1471-2407